Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Open Access
- 28 June 2019
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 17 (5) , 723-732
Abstract
Objectives In Canada, incidences of herpes zoster (HZ) and postherpetic neuralgia (PHN) are increasing, posing a significant burden on the healthcare system. This study aimed to determine the public health impact and cost effectiveness of an adjuvanted recombinant zoster vaccine (RZV) compared to no vaccination and to the live attenuated vaccine (ZVL) in Canadians aged 60 years and older. Methods A multi-cohort Markov model has been adapted to the Canadian context using recent demographic and epidemiologic data. Simulations consisted of age-cohorts annually transitioning between health states. Health outcomes and costs were discounted at 1.5% per year. The perspective of the Canadian healthcare payer was adopted. A coverage of 80% for the first RZV and ZVL dose and a compliance of 75% for the second RZV dose were assumed. Results RZV was estimated to be cost effective compared with no vaccination with an incremental cost-effectiveness ratio (ICER) of $28,360 (Canadian dollars) per quality-adjusted life-year (QALY) in persons aged ≥ 60 years, avoiding 554,504 HZ and 166,196 PHN cases. Compared with ZVL, RZV accrued more QALYs through the remaining lifetime and an increase in costs of approximately $50 million resulting in an average ICER of $2396. Results were robust under deterministic and probabilistic sensitivity analyses. HZ incidence rate and persistence of vaccine efficacy had the largest impact on cost effectiveness. Conclusions The cost-utility analysis suggested that RZV would be cost effective in the Canadian population compared with no vaccination and vaccination with ZVL at a willingness-to-pay threshold of $50,000.Keywords
Funding Information
- GlaxoSmithKline
This publication has 35 references indexed in Scilit:
- Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled studyVaccine, 2014
- The global epidemiology of herpes zosterNeurology, 2013
- Warfarin and Aspirin in Patients with Heart Failure and Sinus RhythmNew England Journal of Medicine, 2012
- Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 YearsClinical Infectious Diseases, 2012
- Predictors of Postherpetic Neuralgia Among Patients With Herpes Zoster: A Prospective StudyThe Journal of Pain, 2010
- The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective studyCanadian Medical Association Journal, 2010
- Cost Effectiveness of Herpes Zoster Vaccine in CanadaPharmacoEconomics, 2009
- Compliance With Multiple-Dose Vaccine Schedules Among Older Children, Adolescents, and Adults: Results From a Vaccine Safety Datalink StudyAmerican Journal of Public Health, 2009
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Utility Scores for Chronic Conditions in a Community-Dwelling PopulationPharmacoEconomics, 1999